TG Therapeutics saw its IBD SmartSelect Composite Rating jump to 97 Thursday, up from 93 the day before.
Looking For Winning Stocks? How To Invest In Both Bull And Bear Markets
The revised score means the stock currently tops 97% of all other stocks in terms of key performance metrics and technical strength. History shows the top market performers tend to have a 95 or higher score as they launch their major climbs.
TG Therapeutics is currently about 2% above a 36.84 entry from a consolidation.
The stock has an 81 EPS Rating, which means its recent quarterly and longer-term annual earnings growth tops 81% of all stocks.
Its Accumulation/Distribution Rating of D shows moderate selling by institutional investors over the last 13 weeks. Look for the rating to improve to at least a C or better.
The company posted a 0% increase in earnings for Q1. Revenue growth came in at 90%, down from 146% in the previous quarter.
TG Therapeutics earns the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
